Japan
Tokyo and Other Japanese City, Japan
NCT Number: NCT01539265
The purpose of this study is to evaluate the efficacy and the safety of silodosin in urinary calculi patients.
Looking for future studies?
Notify Me20 year and older
All sexes
Interventional
Phase 2
Tokyo and Other Japanese City, Japan
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 4 weeks
Time frame: 4 weeks
Time frame: 4 weeks
Time frame: 4 weeks
Kissei Pharmaceutical Co., Ltd.
Industry
A Randomized, Double-blind, Placebo-controlled, Phase II Study of Silodosin in Patients With Urinary Calculi
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07405502
Calculi, Female Urogenital Diseases
Yozgat, Turkey (Türkiye)
View Trial DetailsNCT03244189
Calculi, Female Urogenital Diseases
Rochester, Minnesota, United States
View Trial DetailsNCT04490343
Calculi, Deep Learning Reconstruction
Amiens, France
View Trial DetailsNCT07052188
Calculi, Female Urogenital Diseases
Adıyaman, Turkey (Türkiye)
View Trial Details